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ilizing immune responses. ML29 is a promissing vaccine to
control LF in West Africa.
doi:10.1016/j.ijid.2008.05.684
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Burkholderia pseudomallei is the etiological agent of
melioidosis, a severe invasive disease of humans and ani-
mals in subtropical areas and northern Australia. There is
an urgent need to develop effective therapeutic molecules
against the pathogen for better management of melioidosis.
We undertook to survey for all potential B. pseudoma-
llei immunogenic proteins in order to dissect the bacterial
pathogenesis and evaluate vaccine candidates. In the
present study, a B. pseudomallei clinical isolate (D286)
genomic expression library was constructed and 109 sero-
reactive clones were identiﬁed from the library screened
with pooled melioidosis patients’ sera. DNA sequence
analysis of the seropositive clones revealed 109 putative
immunogenic proteins that were annotated and delin-
eated into functional classes of cell envelope components,
protein secretion and cell motility, transcription, amino
acid transport and metabolism, inorganic ion transport
and metabolism, energy production, protein metabolism,
nucleic acid metabolism and repair, unknown function hypo-
thetical proteins, and other metabolism and transporter
proteins. The complete open reading frame of an immuno-
genic putative outer membrane protein (Oma) was cloned,
expressed and shown to maintain immuno-reactivity with
patient sera. Up to 80% of BALB/c mice immunized with
recombinant Oma were protected from infectious chal-
lenge with 10xLD50 of B. pseudomallei D286, compared with
non-immunized mouse. Therefore, the utility of Oma as a
potential prophylactic agent for melioidosis is proposed.
Mouse anti-Oma polyclonal serum conﬁrmed the presence of
wild type Oma in B. pseudomallei lysate. In addition, pro-
tein sequence analysis revealed that Oma is a member of the
Omp85 family and is highly conserved among species within
the Burkholderia genus, suggesting its suitability as a univer-
sal vaccine candidate or diagnostic epitope for Burkholderia
spp. Characterization of the B. pseudomallei immunome has
shed new light on unraveling the bacterium’s pathogenic
mechanism and disease severity. These immunogens can be
further evaluated as vaccine and serodiagnostic candidates
as well as drug targets.
doi:10.1016/j.ijid.2008.05.685
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Background: It is known that the attenuated polio vac-
cine viruses derived from oral poliovirus vaccine undergo
neurovirulent reversion during repeated replication in the
human alimentary tract, and some paralytic cases caused by
the revertants have been reported. Furthermore, the rever-
tants are excreted with the feces into the environment, and
the viruses have caused new epidemics of poliomyelitis in
the world. It is an obstacle for the achievement of polio
eradication program.
Objective: In this study, to elucidate the reversion mech-
anism of polio vaccine virus to the neurovirulent genotype in
the human alimentary tract, an accumulation of the rever-
sion of the vaccine viruses passaged in cultivation cells which
were derived from the human alimentary tract was ana-
lyzed.
Methods: Polio vaccine viruses were passaged three times
in Caco-2 cells derived from human colon carcinoma. The
reversion of the passaged viruses was analyzed by the
‘‘mutant analysis by PCR and restriction enzyme cleavage
(MAPREC)’’ method designated to estimate the ratio of
revertants in a virus population.
Results: The accumulation of reversion in the vaccine
viruses increased rapidly with viruses passaged at a tem-
perature of 37 ◦C compared with those at 34 ◦C. However,
it was hardly observed in viruses passaged in HEp-2 cells
which were derived from human laryngeal carcinoma at a
temperature of 37 ◦C.
Conclusion: A large difference was observed in the fre-
quency of reversion between Caco-2 and HEp-2 cells though
both cells were derived from human carcinoma. It is impor-
tant to elucidate the cellular factors which take part in the
reversion frequency of the virus genome. Such research is
expected to lead to the elucidation of the reversion mecha-
nism and to the development of a controlling expedient for
the neurovirulent reversion of the polio vaccine virus.
doi:10.1016/j.ijid.2008.05.686
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Current egg-based inﬂuenza vaccine production technol-
ogy is labor-intensive and lack of ﬂexibility and its capacity
would not be able to meet the demand during inﬂuenza
pandemics. Therefore, vaccine production using mammalian
cell technology is becoming viable and attractive. The cur-
rent inﬂuenza H5N1 vaccine strain (NIBRG-14) could grow
efﬁciently in chicken embroyonated eggs and MDCK cells
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(∼108 TCID50/ml) but not in Vero cells (105—6 TCID50/ml)
which is the most common cell line for manufacturing
human vaccines. After several passages and plaque puriﬁca-
tions, two Vero-adapted high growth inﬂuenza H5N1 vaccine
viruses (Vero-15 and Vero-16) have been selected and could
reach high virus titer (108 TCID50/ml) in Vero cells in T
ﬂasks. After tested with NIBRG-14 standard antiserum pro-
vided by the NIBSC, antigenicity of the Vero-15 and Vero-16
viruses remain similar to the NIBRG-14 virus. In addition,
the Vero-15 and Vero-16 viruses do not have any nucleotide
difference in HA and NA gene segments compared with the
NIBRG-14. For process development, Vero cells were fur-
ture cultured on cytodex 1 microcarriers in spinner ﬂasks.
Vero cells growed to 3× 106 cells/ml with a seeding density
of 4.4× 105 cells/ml in 5 g/L microcarriers and peak virus
titers reached 109 TCID50/ml. In conclusion, the Vero-15 and
Vero-16 viruses are suitable for production of inﬂuenza H5N1
vaccines in Vero cells. Their other six internal gene segments
could also be used to generate vaccine seed viruses of other
inﬂuenza subtypes for production in Vero cells.
doi:10.1016/j.ijid.2008.05.687
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Streptococcus pneumoniae (pneumococcus) is an impor-
tant pathogen that causes pneumonia, meningitis and otitis
media. Invasive diseases usually follow colonization of the
respiratory tract and may be favored by factors that cause
immunosupression. Several pneumococcal proteins actively
participate of these events playing different roles such as
facilitating bacterial adhesion to epithelial cells or evasion
from the immune system. Pneumococcal Surface protein
C (PspC) is a virulence factor that has been implicated
both in colonization and in invasive phases of pneumococcal
diseases. Antigen delivery systems based on live recombi-
nant lactic acid bacteria represents a promising strategy
for mucosal vaccination, since they are able to elicit both
systemic and mucosal immune responses. In the present
work, we have evaluated the immune response and the
protective activity of nasal vaccines composed of recom-
binant PspC (rPspC) or Lactobacillus casei expressing PspC
(L.c.PspC). Nasal immunization of mice with both formula-
tions did not elicit the production of anti-PspC IgG or IgA.
On the other hand, ELISPOT and cytokine ELISA analysis of
cultures obtained from mice 13 h after intranasal challenge
with a virulent pneumococcal strain, showed an increase
in IFN- secretion in lung cells from mice immunized with
L.c.PspC and to a lesser extent, rPspC. This cytokine was also
produced by spleen cells from mice immunized with both
formulations. Production of IL-17 by lung cells was observed
in the group immunized with rPspC whereas immuniza-
tion with L.c.PspC induced the production of this cytokine
only by spleen cells. IL-17 has already been implicated in
the protection against colonization conferred by a cellular
pneumococcal vaccine. Nevertheless, the induction of this
cytokine or IFN- by our vaccines did not confer protection
against an invasive challenge with pneumococci. Further
studies will be necessary for the evaluation of protection
against nasal colonization.
Financial Support: FAPESP, Fundac¸ão Butantan, Millenium
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Since 1997, large epidemics of EV71 infection have been
reported in East and Southeast Asia. The virus has caused
numbers of outbreak and infection associated with fatal neu-
rological complications, however no vaccine nor antiviral
against EV71 are available. In our study, we have devel-
oped DNA-based vaccines against EV71. The vaccines consist
of structural protein VP1 of human enterovirus 71 (EV71)
as fusion proteins with enhanced green ﬂuorescent protein
(EGFP), with and without the presence of internal ribosome
entry site (IRES) at the 5′-end; IRESVP1/EGFP and VP1/EGFP.
Expressions of both constructs were evaluated in vitro using
Vero and SK-N-MC cells, and later in vivo in murine model.
Evaluation of in vitro expression showed that the VP1 gene
expressed by 5′UTR-VP1/EGFP is higher in comparison to
construct without IRES; VP1/EGFP, in both Vero and SK-N-MC
cells. The ability of the constructed DNA vaccines in elicit-
ing immune responses were evaluated in vivo using murine
model. Themice were immunized with 2 dosages of DNA vac-
cine followed by experimental challenge. In vivo evaluation
showed that the mice group immunized with IRESVP1/EGFP
confer a higher neutralizing antibody titer in comparison to
the VP1/EGFP. Results from our study not only demonstrate
the potential of VP1-based DNA vaccine but also suggests the
feasibility of using IRES to generate better protective immu-
nity in mice against EV71 and the possibility to develop safe
vaccine against enterovirus infection.
doi:10.1016/j.ijid.2008.05.689
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Background: Since rabies virus (RV) infection is fatal
for both human and animals, the protective immunization
by vaccines is of critical importance for disease con-
trol and prevention. Several recombinant protein and live
viruses of rabies have been constructed and tested for their
